In the first nine months of fiscal 2021-22, the IBN Sina Pharmaceutical Industry, a subsidiary of IBN Sina Trust, saw a 21 percent increase in profit as its business continued to develop.
According to a financial statement released on Thursday, the company’s consolidated profit increased to Tk41.43 crore from Tk34.17 crore the previous year rising by more than 21 per cent. The consolidated earnings per share (EPS) was Tk13.26, up from Tk10.92 in fiscal 2020-21’s July-March period showing a growth of more than 21 per cent.
Its consolidated profit increased by 24 per cent in fiscal 2020-21 compared to the previous year, owing to an increase in medicine sales due to the Covid-19 epidemic. It has paid a 47 per cent cash dividend to its shareholders based on the earnings increase, the greatest for the company in the last twelve years since 2009. It operates two manufacturing plants, one for pharmaceuticals and the other for natural medicines.
Source for more details:
